Corrigendum to "Understanding the muscular dystrophy caused by deletion of choline kinase beta in mice" [Biochim. Biophys. Acta 1791 (2009) 347-356] (DOI:10.1016/j.bbalip.2009.02.006);Understanding the muscular dystrophy caused by deletion of choline kinase beta in mice

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1791, Issue 5, 2009, Pages 347-356

  Wu, Gengshu ^a   Sher, Roger B ^b   Cox, Gregory A ^b   Vance, Dennis E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b JACKSON LABORATORY   (United States)

Author keywords

Cardiotoxin; CDP choline; Choline kinase; CTP:phosphocholine cytidylyltransferase; Muscular dystrophy; Phosphatidylcholine; Phospholipase

Indexed keywords

BETAINE; CARDIOTOXIN; CHOLINE; CHOLINE KINASE; CHOLINE KINASE BETA; CHOLINE PHOSPHATE CYTIDYLYLTRANSFERASE; CITICOLINE; CREATINE KINASE; CYCLINE; MYOSTATIN; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE; SOMATOMEDIN C; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CATABOLISM; CELL CULTURE; CHKA GENE; CHKB GENE; ENZYME ASSAY; GASTROCNEMIUS MUSCLE; GENE; HINDLIMB; IMMUNOBLOTTING; KNOCKOUT MOUSE; LEG MUSCLE; LIPID ANALYSIS; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; MUSCLE INJURY; MUSCULAR DYSTROPHY; MYOBLAST; NONHUMAN; PHOSPHOLIPID SYNTHESIS; PRIORITY JOURNAL;

MURINAE; MUS;

ANIMALS; CELLS, CULTURED; CHOLINE KINASE; CREATINE KINASE; CYTIDINE DIPHOSPHATE CHOLINE; GENE DELETION; HINDLIMB; INSULIN-LIKE GROWTH FACTOR I; MICE; MITOCHONDRIA; MUSCLES; MUSCULAR DYSTROPHIES; MYOBLASTS; MYOSTATIN; PHOSPHATIDYLCHOLINES; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTORS, LIPOPROTEIN; REGENERATION; SUBSTRATE SPECIFICITY;

EID: 64749088438     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2009.11.001     Document Type: Erratum

References (66)

1. Cohn R.D., and Campbell K.P. Molecular basis of muscular dystrophies. Muscle Nerve 23 (2000) 1456-1471
2. Sher R.B., Aoyama C., Huebsch K.A., Ji S., Kerner J., Yang Y., Frankel W.N., Hoppel C.L., Wood P.A., Vance D.E., and Cox G.A. A rostrocaudal muscular dystrophy caused by a defect in choline kinase beta, the first enzyme in phosphatidylcholine biosynthesis. J. Biol. Chem. 281 (2006) 4938-4948
3. Cuadrado A., Carnero A., Dolfi F., Jimenez B., and Lacal J.C. Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. Oncogene 8 (1993) 2959-2968
4. Aoyama C., Liao H., and Ishidate K. Structure and function of choline kinase isoforms in mammalian cells. Prog. Lipid Res. 43 (2004) 266-281
5. Ishidate K., Enosawa S., and Nakazawa Y. Actinomycin D-sensitive induction of choline kinase by carbon tetrachloride intoxication in rat liver. Biochem. Biophys. Res. Commun. 111 (1983) 683-689
6. Wu G., Aoyama C., Young S.G., and Vance D.E. Early embryonic lethality caused by disruption of the gene for choline kinase alpha, the first enzyme in phosphatidylcholine biosynthesis. J. Biol. Chem. 283 (2008) 1456-1462
7. Chan D.C. Mitochondria: dynamic organelles in disease, aging, and development. Cell 125 (2006) 1241-1252
8. Kwong J.Q., Beal M.F., and Manfredi G. The role of mitochondria in inherited neurodegenerative diseases. J. Neurochem. 97 (2006) 1659-1675
9. Lin M.T., and Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443 (2006) 787-795
10. Filosto M., Tomelleri G., Tonin P., Scarpelli M., Vattemi G., Rizzuto N., Padovani A., and Simonati A. Neuropathology of mitochondrial diseases. Biosci. Rep. 27 (2007) 23-30
11. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
12. Bligh E.G., and Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37 (1959) 911-917
13. McCluer R.H., Ullman M.D., and Jungalwala F.B. HPLC of glycosphingolipids and phospholipids. Adv. Chromatogr. 25 (1986) 309-353
14. Ishidate K., and Nakazawa Y. Choline/ethanolamine kinase from rat kidney. Methods Enzymol. 209 (1992) 121-134
15. Aoyama C., Ohtani A., and Ishidate K. Expression and characterization of the active molecular forms of choline/ethanolamine kinase-alpha and -beta in mouse tissues, including carbon tetrachloride-induced liver. Biochem. J. 363 (2002) 777-784
16. Weinhold P.A., and Feldman D.A. Choline-phosphate cytidylyltransferase. Methods Enzymol. 209 (1992) 248-258
17. Nakagami K., Uchida T., Ohwada S., Koibuchi Y., Suda Y., Sekine T., and Morishita Y. Increased choline kinase activity and elevated phosphocholine levels in human colon cancer. Jpn. J. Cancer Res. 90 (1999) 419-424
18. Rouser G., Fkeischer S., and Yamamoto A. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 5 (1970) 494-496
19. Diaz F., Thomas C.K., Garcia S., Hernandez D., and Moraes C.T. Mice lacking COX10 in skeletal muscle recapitulate the phenotype of progressive mitochondrial myopathies associated with cytochrome c oxidase deficiency. Hum. Mol. Genet. 14 (2005) 2737-2748
20. Springer M.L., Rando T., and Blau H.M. Gene Delivery to Muscle, Current Protocols in Human Genetics. Unit 13.4 (1997), John Wiley & Sons, New York
21. Li Z., Agellon L.B., Allen T.M., Umeda M., Jewell L., Mason A., and Vance D.E. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab. 3 (2006) 321-331
22. D.E. Vance, J.E. Vance, Phospholipid Biosynthesis in Eucaryotes. In Biochemistry of Lipids, Lipoproteins and Membranes, 5th ed. (Vance, D.E., and Vance, J.E., eds), pp.213-244, Elsevier Science, Amsterdam.
23. Wakabayashi T. Megamitochondria formation - physiology and pathology. J. Cell. Mol. Med. 6 (2002) 497-538
24. McNally E.M., and Pytel P. Muscle diseases: the muscular dystrophies. Annu. Rev. Pathol. 2 (2007) 87-109
25. Engvall E., and Wewer U.M. The new frontier in muscular dystrophy research: booster genes. FASEB J. 17 (2003) 1579-1584
26. Huard J., Li Y., and Fu F.H. Muscle injuries and repair: current trends in research. J. Bone Joint Surg. Am. 84-A (2002) 822-832
27. Carnac G., Ricaud S., Vernus B., and Bonnieu A. Myostatin: biology and clinical relevance. Mini Rev. Med. Chem. 6 (2006) 765-770
28. Bogdanovich S., McNally E.M., and Khurana T.S. Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C. Muscle Nerve 37 (2008) 308-316
29. Tobin J.F., and Celeste A.J. Myostatin, a negative regulator of muscle mass: implications for muscle degenerative diseases. Curr. Opin. Pharmacol. 5 (2005) 328-332
30. McPherron A.C., and Lee S.J. Suppression of body fat accumulation in myostatin-deficient mice. J. Clin. Invest. 109 (2002) 595-601
31. Lin Shiau S.Y., Huang M.C., and Lee C.Y. Mechanism of action of cobra cardiotoxin in the skeletal muscle. J. Pharmacol. Exp. Ther. 196 (1976) 758-770
32. Fletcher J.E., Jiang M.S., Gong Q.H., Yudkowsky M.L., and Wieland S.J. Effects of a cardiotoxin from Naja naja kaouthia venom on skeletal muscle: involvement of calcium-induced calcium release, sodium ion currents and phospholipases A2 and C. Toxicon 29 (1991) 1489-1500
33. Chen S.E., Gerken E., Zhang Y., Zhan M., Mohan R.K., Li A.S., Reid M.B., and Li Y.P. Role of TNF-{alpha} signaling in regeneration of cardiotoxin-injured muscle. Am. J. Physiol. Cell Physiol. 289 (2005) C1179-C1187
34. Couteaux R., Mira J.C., and d'Albis A. Regeneration of muscles after cardiotoxin injury. I. Cytological aspects. Biol. Cell 62 (1988) 171-182
35. Hove E.L., and Copeland D.H. Progressive muscular dystrophy in rabbits as a result of chronic choline deficiency. J. Nutr. 53 (1954) 391-405
36. Kwok C.T., and Austin L. Phospholipid composition and metabolism in mouse muscular dystrophy. Biochem. J. 176 (1978) 15-22
37. Kwok C.T., Kuffer A.D., Tang B.Y., and Austin L. Phospholipid metabolism in murine muscular dystrophy. Exp. Neurol. 50 (1976) 362-375
38. Austin L., Kwok C.T., Kuffer A.D., and Tang B.Y. Phospholipid metabolism in murine muscular dystrophy. Adv. Exp. Med. Biol. 72 (1976) 367-372
39. Mori N., Glunde K., Takagi T., Raman V., and Bhujwalla Z.M. Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res. 67 (2007) 11284-11290
40. Porta E.A., Bergman B.J., and Stein A.A. Acute alcoholic hepatitis. Am. J. Pathol. 46 (1965) 657-689
41. Sun C.N., Dhalla N.S., and Olson R.E. Formation of gigantic mitochondria in hypoxic isolated perfused rat hearts. Experientia 25 (1969) 763-764
42. Tandler B., Erlandson R.A., and Wynder E.L. Riboflavin and mouse hepatic cell structure and function. I. Ultrastructural alterations in simple deficiency. Am. J. Pathol. 52 (1968) 69-96
43. Guo W.X., Pye Q.N., Williamson K.S., Stewart C.A., Hensley K.L., Kotake Y., Floyd R.A., and Broyles R.H. Mitochondrial dysfunction in choline deficiency-induced apoptosis in cultured rat hepatocytes. Free Radic. Biol. Med. 39 (2005) 641-650
44. Karbowski M., Kurono C., Wozniak M., Ostrowski M., Teranishi M., Nishizawa Y., Usukura J., Soji T., and Wakabayashi T. Free radical-induced megamitochondria formation and apoptosis. Free Radic. Biol. Med. 26 (1999) 396-409
45. Wakabayashi T., Yamashita K., Adachi K., Kawai K., Iijima M., Gekko K., Tsudzuki T., Popinigis J., and Momota M. Changes in physicochemical properties of mitochondrial membranes during the formation process of megamitochondria induced by hydrazine. Toxicol. Appl. Pharmacol. 87 (1987) 235-248
46. Kiebish M.A., Han X., Cheng H., Chuang J.H., and Seyfried T.N. Cardiolipin and electron transport chain abnormalities in mouse brain tumor mitochondria: lipidomic evidence supporting the Warburg theory of cancer. J. Lipid. Res. 49 (2008) 2545-2556
47. Bobyleva V., Bellei M., Pazienza T.L., and Muscatello U. Effect of cardiolipin on functional properties of isolated rat liver mitochondria. Biochem. Mol. Biol. Int. 41 (1997) 469-480
48. Ohtsuka T., Nishijima M., Suzuki K., and Akamatsu Y. Mitochondrial dysfunction of a cultured Chinese hamster ovary cell mutant deficient in cardiolipin. J. Biol. Chem. 268 (1993) 22914-22919
49. Daum G. Lipids of mitochondria. Biochim. Biophys. Acta 822 (1985) 1-42
50. Miyake M., Hayashi S., Sato T., Taketa Y., Watanabe K., Tanaka S., Ohwada S., Aso H., and Yamaguchi T. Myostatin and MyoD family expression in skeletal muscle of IGF-1 knockout mice. Cell Biol. Int. 31 (2007) 1274-1279
51. Dasarathy S., Dodig M., Muc S.M., Kalhan S.C., and McCullough A.J. Skeletal muscle atrophy is associated with an increased expression of myostatin and impaired satellite cell function in the portacaval anastamosis rat. Am. J. Physiol.: Gasterointest. Liver Physiol. 287 (2004) G1124-G1130
52. Bogdanovich S., Krag T.O., Barton E.R., Morris L.D., Whittemore L.A., Ahima R.S., and Khurana T.S. Functional improvement of dystrophic muscle by myostatin blockade. Nature 420 (2002) 418-421
53. Whittemore L.A., Song K., Li X., Aghajanian J., Davies M., Girgenrath S., Hill J.J., Jalenak M., Kelley P., Knight A., Maylor R., O'Hara D., Pearson A., Quazi A., Ryerson S., Tan X.Y., Tomkinson K.N., Veldman G.M., Widom A., Wright J.F., Wudyka S., Zhao L., and Wolfman N.M. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem. Biophys. Res. Commun. 300 (2003) 965-971
54. Joulia-Ekaza D., and Cabello G. Myostatin regulation of muscle development: molecular basis, natural mutations, physiopathological aspects. Exp. Cell Res. 312 (2006) 2401-2414
55. McPherron A.C., Lawler A.M., and Lee S.J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387 (1997) 83-90
56. Gonzalez-Cadavid N.F., Taylor W.E., Yarasheski K., Sinha-Hikim I., Ma K., Ezzat S., Shen R., Lalani R., Asa S., Mamita M., Nair G., Arver S., and Bhasin S. Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 14938-14943
57. Matsakas A., and Diel P. The growth factor myostatin, a key regulator in skeletal muscle growth and homeostasis. Int. J. Sports Med. 26 (2005) 83-89
58. Wagner K.R., Liu X., Chang X., and Allen R.E. Muscle regeneration in the prolonged absence of myostatin. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2519-2524
59. Adibhatla R.M., and Hatcher J.F. Cytidine 5′-diphosphocholine (CDP-choline) in stroke and other CNS disorders. Neurochem. Res. 30 (2005) 15-23
60. Adibhatla R.M., and Hatcher J.F. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J. Neurosci. Res. 70 (2002) 133-139
61. Adibhatla R.M., Hatcher J.F., and Tureyen K. CDP-choline liposomes provide significant reduction in infarction over free CDP-choline in stroke. Brain Res. 1058 (2005) 193-197
62. Cacabelos R., Caamano J., Gomez M.J., Fernandez-Novoa L., Franco-Maside A., and Alvarez X.A. Therapeutic effects of CDP-choline in Alzheimer's disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. Ann. N.Y. Acad. Sci. 777 (1996) 399-403
63. Eberhardt R., Birbamer G., Gerstenbrand F., Rainer E., and Traegner H. Citicoline in the treatment of Parkinson's disease. Clin. Ther. 12 (1990) 489-495
64. Adibhatla R.M., Hatcher J.F., and Dempsey R.J. Citicoline: neuroprotective mechanisms in cerebral ischemia. J. Neurochem. 80 (2002) 12-23
65. Adibhatla R.M., Hatcher J.F., Larsen E.C., Chen X., Sun D., and Tsao F.H. CDP-choline significantly restores phosphatidylcholine levels by differentially affecting phospholipase A2 and CTP: phosphocholine cytidylyltransferase after stroke. J. Biol. Chem. 281 (2006) 6718-6725
66. Fioravanti M., and Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst. Rev. (2005) CD000269